Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

(2012) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS

Acute Progression of BCR-FGFR1 Induced Murine B-Lympho/Myeloproliferative Disorder Suggests Involvement of Lineages at the Pro-B Cell Stage

(2012) MingQiang Ren et al.   PLoS One

Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease

(2011) M. Ren et al.   BLOOD

Src Activation Plays an Important Key Role in Lymphomagenesis Induced by FGFR1 Fusion Kinases

(2011) M. Ren et al.   CANCER RESEARCH

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

(2011) B. Wasag et al.   HAEMATOLOGICA

The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation

(2011) Ailsa Holroyd et al.   LEUKEMIA RESEARCH

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

(2011) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS

8p11 myeloproliferative syndrome: a review

(2010) Courtney C. Jackson et al.   HUMAN PATHOLOGY

t(8;13)-positive Bilineal Lymphomas

(2009) Francisco Vega et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase

(2009) M. Ren et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL